Summary of the US FDA approval of belatacept
- PMID: 22335273
- DOI: 10.1111/j.1600-6143.2011.03976.x
Summary of the US FDA approval of belatacept
Abstract
Elements of the Food and Drug Administration (FDA) review of the clinical data that supported the approval of the Biologics License Application (BLA) for belatacept for prophylaxis of organ rejection in adult patients receiving a kidney transplant are summarized. The article is not intended as a comprehensive summary of the entire belatacept data submission. Rather, the discussion is meant to illustrate aspects of the FDA's process for evaluating efficacy and safety, using belatacept as an example.
© copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.
Comment in
-
Beyond belatacept: praise and progress for the FDA.Am J Transplant. 2012 Mar;12(3):513-4. doi: 10.1111/j.1600-6143.2011.03975.x. Epub 2012 Feb 15. Am J Transplant. 2012. PMID: 22335245 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
